Impact Biomedical (IBO) Receivables - Net (2024 - 2025)
Impact Biomedical's (IBO) quarterly Receivables - Net came in at $5000.0 in Q4 2025, down 97.51% YoY from $201000.0 in Q4 2024, and down 97.49% on a QoQ basis from $199000.0 in Q3 2025.
Impact Biomedical (IBO) Receivables - Net (2024 - 2025) Analysis & Trends
Impact Biomedical (IBO) has 2 years of Receivables - Net data on file, last reported at $5000.0 in Q4 2025.
- Quarterly Receivables - Net fell 97.51% year-over-year to $5000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5000.0 (down 97.51% YoY) and the FY2025 annual result came in at $5000.0, down 97.51% from the prior year.
- Receivables - Net eased to $5000.0 in Q4 2025, from $199000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $201000.0 in Q4 2024 to a low of $5000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Sep 30, 2025 | 199,000.00 |
| Sep 30, 2025 | 199,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Jun 30, 2024 | 128,000.00 |
| Jun 30, 2024 | 128,000.00 |
| Mar 31, 2024 | 128,000.00 |
| Mar 31, 2024 | 128,000.00 |